The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Benson on Challenges of Active Surveillance for Prostate Cancer
March 16th 2015Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.
PD-1 Pathway Combos Lead the Way in RCC Immunotherapy
March 16th 2015The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.
Noted Astronaut Addresses Importance of Teamwork at Prostate Congress
In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.
Dr. Scholz on Using Abiraterone in mCRPC
March 4th 2015Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Dixon Questions Value of Chemoprevention With Tamoxifen
March 3rd 2015The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.
The Doctor Will Tweet With You Now: Social Media for Oncologists
March 3rd 2015Deanna J. Attai, MD, FACS, who interacts with her thousands of followers on Twitter, Facebook, YouTube, her blog, and other social media platforms, recently educated other physicians on what their role can be on social media.
Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer
March 2nd 2015Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.
Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms
March 2nd 2015A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.
Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC
An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.
Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer
February 28th 2015Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.
Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients
February 28th 2015Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.
Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective
February 28th 2015Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.
Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer
February 28th 2015In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.
Second-Line Ramucirumab Plus Docetaxel in Urothelial Cancer Improves Progression-Free Survival
Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.
Dr. Carey on Treating Triple-Negative Breast Cancer
February 28th 2015Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.